- No FAQs found
- ABL Kinase Domain Mutation in CML, Cell-based
- ABO Group and Rh Type
- Acid-Fast Bacillus (AFB) Identification, Sequencing and Stain, Paraffin Block
- ADAMTS13 Activity with Reflex to ADAMTS13 Inhibitor
- Alcohol Metabolites, Quantitative, Urine
- Alpha-Globin Common Mutation Analysis
- Alpha-Globin Gene Deletion or Duplication
- Alpha-Globin Gene Sequencing
- Anti-Müllerian Hormone AssessR™
- Anti-PF4 and Serotonin Release Assay (SRA) for Diagnosing Heparin-induced Thrombocytopenia/Thrombosis (HIT/HITT)
- Antiphospholipid Antibodies
- ASCVD Risk Panel with Score
- Autoimmune Epilepsy Evaluation
- Autoimmune Diseases, Tests for
- B-cell and T-cell Clonality Assays by PCR
- B-Type Natriuretic Peptide (BNP)
- BCR-ABL1 Gene Rearrangement, Quantitative PCR
- Beta-Globin Complete
- Biotin: Interference with Laboratory Assays
- BRCAvantage®, Ashkenazi Jewish Screen
- BRCAvantage®, Rearrangements
- BRCAvantage™, Comprehensive
- BRCAvantage™, Single Site
- CDH1 Sequencing and Deletion/Duplication
- Clostridium difficile Diagnostic Testing
- C1 Inhibitor, Protein and Functional Tests
- Calreticulin (CALR) Mutation Analysis
- Carbapenem Resistant Enterobacteriaceae Culture Screen
- Cervical Cancer, TERC, FISH
- CFvantage® Cystic Fibrosis Expanded Screen
- Chlamydia trachomatis, TMA
- Chlamydia trachomatis/Neisseria gonorrhoeae RNA, TMA
- Chromosomal Microarray, POC, ClariSure®, Oligo-SNP
- Chromosomal Microarray, Postnatal, ClariSure® Oligo-SNP
- Chromosome Analysis and AFP with Reflex to AChE, Fetal Hgb, Amniotic Fluid
- Chromosome Analysis, Amniotic Fluid
- Chromosome Analysis, Blood
- Chromosome Analysis, Blood with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Chorionic Villus Sample
- Chromosome Analysis, High Resolution
- Chromosome Analysis, High Resolution with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Mosaicism
- Chromosome Analysis, Neonatal Blood
- Chromosome Analysis, Sister Chromatid Exchange
- Chromosome Analysis, Tissue
- Chromosome DEB Assay for Fanconi anemia
- Chronic Lymphocytic Leukemia (CLL) - Diagnostic and Prognostic Testing
- Culture, Fungus
- Culture, Urine, Routine
- Cystic Fibrosis Screen
- Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) PCR
- D-Dimer, Quantitative
- Dementia, Secondary Causes
- Dengue Virus Testing
- Diabetes Risk Panel with Score and Cardio IQ® Diabetes Risk Panel with Score
- Drug Testing, General Toxicology (Blood, Urine, or Serum)
- Drug Toxicology Alcohol Metab, QN, Oral Fluid
- Drug Toxicology Monitoring, Oral Fluid Testing
- Factor V (Leiden) Mutation Analysis
- Familial Hypercholesterolemia (FH) Panel
- Familial Hypercholesterolemia (FH) Single Site
- Familial Mediterranean Fever Mutation Analysis
- First Trimester Screen, hCG
- First Trimester Screen, Hyperglycosylated hCG (h-hCG)
- FISH, Angelman
- FISH, MET Amplification
- FISH, Myeloma, 17p-, rea 14q32 with Reflexes
- FISH, Prader-Willi
- FISH, Prenatal Screen
- No FAQs found
- HCV Genotyping
- Helicobacter pylori (H pylori) Antibody Discontinuation
- Heparin, Anti-Xa
- Hepatitis B Surface Antibody, Quantitative
- Hepatitis B Surface Antigen, Quantitative, Monitoring
- Hepatitis C Antibody with Reflex to HCV RNA, PCR with Reflex to Genotype
- Hepatitis C Viral RNA Genotype 1 NS5A Drug-resistance
- Hepatitis C Viral RNA Genotype 3 NS5A Drug Resistance
- Hepatitis C Viral RNA NS3 Drug Resistance
- Hepatitis C Virus Antibody and RNA Testing
- Hereditary Cancer Panels: MYvantageTM Hereditary Comprehensive Cancer Panel and GIvantageTM Hereditary Colorectal Cancer Panel
- Hereditary Hemochromatosis DNA Mutation Analysis
- Herpes Simplex Virus (HSV) Type-Specific IgG Antibodies
- Herpes Simplex Virus Type 2 (HSV-2) IgG Inhibition, ELISA
- HIV-1 Coreceptor Tropism, Proviral DNA
- HIV-1 Coreceptor Tropism, Ultradeep Sequencing
- HIV-1 Integrase Genotype
- HIV-1 Resistance, Proviral DNA (RTI, PI, Integrase Inhibitors)
- HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes
- HPV mRNA E6/E7
- Infliximab and Adalimumab Drug and Anti-drug Antibody Testing
- Influenza A and B Antigen, Immunoassay
- Influenza Type A and B Antibodies
- Insulin, Intact, LC/MS/MS
- Integrated Screen, Part 1
- Integrated Screen, Part 2
- Intrinsic Factor Blocking Antibody
- No FAQs found
- No FAQs found
- Maternal Serum AFP
- Melanoma, BRAF V600E and V600K Mutation Analysis, THxID®
- Metanephrines, Fractionated, Free, LC/MS/MS, Plasma
- Methylenetetrahydrofolate Reductase (MTHFR), DNA Analysis
- Microalbumin (Urinary Albumin Excretion)
- Pain Management and CYP2D6/CYP2C19
- Pain Management Antidepressants, With Confirmation, Urine
- Pain Management Antipsychotics, With Confirmation, Serum and Urine
- Pain Management, Naltrexone, Quantitative, Urine
- Partial Thromboplastin Time, Activated (aPTT)
- Penta Screen
- PIK3CA Mutation Analysis
- Platelet Antibody Screen (Indirect)
- PNH with FLAER (High Sensitivity)
- Prothrombin Time with INR
- PTH, Intact and Calcium
- Streptococcus pneumoniae (Pneumococcal) Antibody Tests
- Saccharomyces cerevisiae Antibodies (ASCA) (IgG, IgA)
- Sequential Integrated Screen, Part 1
- Sequential Integrated Screen, Part 2
- Serum Integrated Screen, Part 1
- Serum Integrated Screen, Part 2
- Serum Pregnancy Tests
- Sickle Cell Screen
- Stepwise, Part 1
- Stepwise, Part 2
- SureSwab® Trichomonas vaginalis RNA, Qualitative TMA
- SureSwab®, Candidiasis, PCR
- TP53 Sequencing and Deletion/Duplication
- T4, Free
- Tamoxifen and Metabolites, LC-MS/MS
- Testosterone Testing
- Total Testosterone, LC/MS/MS
- Triple Screen
- No FAQs found
- No FAQs found
- No FAQs found
Cervical Cancer, TERC, FISHTest code(s) 91027
This is an outdated version of this FAQ. It was effective 04/24/2012 to 04/08/2016.
The current version is available here.
Question 1. What is the Cervical Cancer, TERC, FISH assay?
This is a fluorescence in situ hybridization (FISH)-based assay performed using ThinPrep® or SurePath™ cervical cytology samples. This test determines the number of copies of TERC, a telomerase RNA component gene located at chromosome band 3q26. Two fluorescent probes are used to calculate a ratio between copy number for chromosome 3, measured by a peri-centromeric probe (green signals below), and the copies of the TERC gene locus (red signals below). The pattern of these two probes in each cell can thus be scored as non-amplified, TERC-amplified, or polysomic. Interpretation is based on the pattern and number of cells with either abnormal pattern.
Question 2. Why is the TERC gene important in the development of cervical cancer?
There are several important events that occur as cervical cells transition from normal to malignant. The earliest event is initiated by infection of cervical squamous cells by high-risk subtypes of human papilloma virus (HPV). This is followed by chromosomal instability, which manifests as polysomy (ie, increase in chromosome copy number), and by TERC gene amplification.
The earlier HPV-related cellular changes are associated on a Pap smear with koilocytosis and low-grade dysplasia. The later genomic changes, such as genetic instability and TERC amplification, are associated with high-grade squamous intraepithelial neoplasia (HSIL) and progression to invasive carcinoma.
Question 3. When is it appropriate to use the Cervical Cancer, TERC, FISH test?
Consider using this test as an adjunct to Pap smear cytomorphology and high-risk HPV testing, especially when
Your patient has atypical Pap test results, particularly in assessing the significance of ASC-H lesions;
You want to stratify LSIL lesions into those with a higher risk of progression to HSIL
- Your patient has atypical Pap test results with a negative high-risk HPV test result
Question 4. How can this assay help with discordant cytology and HPV results?
This assay can help you decide how best to manage the patient by providing additional information not available from cytology or HPV testing. Since TERC amplification is associated with HSIL, you may wish to consider more intensive follow-up for patients who have an atypical cytology result such as ASC-H that is associated with TERC amplification. Similarly, this assay may provide additional information in patients with atypical Pap findings but absence of high-risk HPV.
Question 5. How will the results of this test help how I manage my patients?
Information provided by this test is additive to cytology findings and largely independent of HPV infection status. Although not included in the ACOG or ASCP guidelines, TERC copy number enumeration has been shown in several large studies summarized below to be useful in predicting progression in SILs. Test results will have the greatest impact on influencing appropriate follow-up interval or treatment plan when Pap test results are equivocal or when cytology and HPV test results are discordant.
Question 6. Are there peer-reviewed journal articles that support the use of TERC amplification testing?
Yes, there have been a number of peer-reviewed journal articles published that establish the power of detecting TERC amplification and using it to further stratify patients with cervical dysplasia. Key references include:
Heselmeyer-Haddad K, et al. Genomic amplification of the human telomerase gene (TERC) in Pap smears predicts the development of cervical cancer. Am J Pathol. 2005;166:1229-1238.
This study of 59 patients with LSIL/CIN1/CIN2 lesions showed that gain of 3q/TERC was associated with progression to CIN3/HSIL rather than regression on follow-up analysis.
Zheng Tu, et al. Genomic amplification of the human telomerase RNA gene for differential diagnosis of cervical disorders. Cancer Genet Cytogenet. 2009;191:10-16.
This large study, that included over 1000 women, demonstrated a strong positive correlation between TERC amplification and advancing lesion grade as determined by both cytopathology and histopathology.
Andersson S, et al. Detection of genomic amplification of the human telomerase gene (TERC), a potential marker for triage of women with HPV-positive, abnormal Pap smears. Am J Pathol. 2009;175:1831-1847.
This study of 78 cytology samples demonstrated positive correlation between TERC amplification and histologically confirmed advancing lesion grade.
Question 7. What sample types can be used?
The test can be performed using residual liquid-based cytology samples (ThinPrep® or SurePath™) collected for Pap testing. These samples can be tested up to 30 days after collection providing an adequate number of cervical epithelial cells can be harvested.
The test cannot be performed on slides from conventional Pap smear samples.
Question 8. What is the sensitivity and specificity of this assay?
The analytical sensitivity and specificity of this assay approach 100%.
In our validation study, TERC amplification or polysomy of chromosome 3 was not observed in cytology samples with normal/benign results, but in ~10% of LSIL, up to 30% of ASC-H and over 90% of HSIL cases. These results are similar to those noted in previous studies correlating alterations of the TERC locus with Pap cytology findings (e.g., Cancer Genet Cytogenet. 2009;191:10-16).
Document FAQS.57 Revision: 0